SEPHS1 and melanoma: Further analysis using the TIP database indicated that high SEPHS1 expression was negatively correlated with multiple steps of the cancer-immunity cycle in tumors such as adrenocortical carcinoma, hepatocellular carcinoma, lung adenocarcinoma, melanoma, and endometrial carcinoma, whereas a partial positive correlation was seen in breast cancer (Figure S7D).